Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration

Patrizia Giannatempo, Gregory R. Pond, Guru Sonpavde, Costantine Albany, Yohann Loriot, Christopher J. Sweeney, Roberto Salvioni, Maurizio Colecchia, Nicola Nicolai, Daniele Raggi, Kevin R. Rice, Chandra K. Flack, Nemer R. El Mouallem, Hope Feldman, Karim Fizazi, Lawrence Einhorn, Richard Foster, Andrea Necchi, K. Clinton Cary

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: We assessed prognostic factors, treatments and outcomes in patients with teratoma with malignant transformation, a rare occurrence among germ cell tumors. Materials and Methods: Data on patients diagnosed with teratoma with malignant transformation between June 1981 and August 2014 were collected across 5 referral centers. Chemotherapy was dichotomized as based on germ cell tumor or teratoma with malignant transformation. Cox analyses were done to evaluate prognostic factors of overall survival, the primary end point. Each factor was evaluated in a univariable model. Forward stepwise selection was used to construct an optimal model. Results: Among 320 patients the tumor primary site was gonadal in 287 (89.7%), retroperitoneal in 17 (5.3%) and mediastinal in 16 (5%). Teratoma with malignant transformation and germ cell tumor were diagnosed concurrently in 130 patients (40.6%). A total of 49 patients (16.8%) initially presented with clinical stage I. The remaining patients were at good (123 or 42.3%), intermediate (42 or 14.4%) and poor (77 or 26.5%) risk for metastasis according to IGCCCG (International Germ Cell Cancer Collaborative Group). First line chemotherapy was given for germ cell tumor in 159 patients (49.7%), chemotherapy for teratoma with malignant transformation was performed in 14 (4.4%) and only surgery was done in 147 (45.9%). Median followup was 25.1 months (IQR 5.4-63.8). Five-year overall survival was 83.4% (95% CI 61.3 to 93.5) in patients with clinical stage I and it was also worse than expected in those with metastasis. On multivariable analyses nonprimitive neuroectodermal tumor histology (overall p = 0.004), gonadal primary tumor (p = 0.005) and fewer prior chemotherapy regimens (p

Original languageEnglish (US)
JournalJournal of Urology
DOIs
StateAccepted/In press - 2016

Fingerprint

Teratoma
Germ Cell and Embryonal Neoplasms
Drug Therapy
Neuroectodermal Tumors
Neoplasm Metastasis
Survival
Neoplasms
Histology
Referral and Consultation

Keywords

  • Cell transformation, neoplastic
  • Drug therapy
  • Neoplasms, germ cell and embryonal
  • Teratoma
  • Testicular neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation : An International Collaboration. / Giannatempo, Patrizia; Pond, Gregory R.; Sonpavde, Guru; Albany, Costantine; Loriot, Yohann; Sweeney, Christopher J.; Salvioni, Roberto; Colecchia, Maurizio; Nicolai, Nicola; Raggi, Daniele; Rice, Kevin R.; Flack, Chandra K.; El Mouallem, Nemer R.; Feldman, Hope; Fizazi, Karim; Einhorn, Lawrence; Foster, Richard; Necchi, Andrea; Cary, K. Clinton.

In: Journal of Urology, 2016.

Research output: Contribution to journalArticle

Giannatempo, P, Pond, GR, Sonpavde, G, Albany, C, Loriot, Y, Sweeney, CJ, Salvioni, R, Colecchia, M, Nicolai, N, Raggi, D, Rice, KR, Flack, CK, El Mouallem, NR, Feldman, H, Fizazi, K, Einhorn, L, Foster, R, Necchi, A & Cary, KC 2016, 'Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration', Journal of Urology. https://doi.org/10.1016/j.juro.2015.12.082
Giannatempo, Patrizia ; Pond, Gregory R. ; Sonpavde, Guru ; Albany, Costantine ; Loriot, Yohann ; Sweeney, Christopher J. ; Salvioni, Roberto ; Colecchia, Maurizio ; Nicolai, Nicola ; Raggi, Daniele ; Rice, Kevin R. ; Flack, Chandra K. ; El Mouallem, Nemer R. ; Feldman, Hope ; Fizazi, Karim ; Einhorn, Lawrence ; Foster, Richard ; Necchi, Andrea ; Cary, K. Clinton. / Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation : An International Collaboration. In: Journal of Urology. 2016.
@article{726ad36b8de74456873997dff4e8b38f,
title = "Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration",
abstract = "Purpose: We assessed prognostic factors, treatments and outcomes in patients with teratoma with malignant transformation, a rare occurrence among germ cell tumors. Materials and Methods: Data on patients diagnosed with teratoma with malignant transformation between June 1981 and August 2014 were collected across 5 referral centers. Chemotherapy was dichotomized as based on germ cell tumor or teratoma with malignant transformation. Cox analyses were done to evaluate prognostic factors of overall survival, the primary end point. Each factor was evaluated in a univariable model. Forward stepwise selection was used to construct an optimal model. Results: Among 320 patients the tumor primary site was gonadal in 287 (89.7{\%}), retroperitoneal in 17 (5.3{\%}) and mediastinal in 16 (5{\%}). Teratoma with malignant transformation and germ cell tumor were diagnosed concurrently in 130 patients (40.6{\%}). A total of 49 patients (16.8{\%}) initially presented with clinical stage I. The remaining patients were at good (123 or 42.3{\%}), intermediate (42 or 14.4{\%}) and poor (77 or 26.5{\%}) risk for metastasis according to IGCCCG (International Germ Cell Cancer Collaborative Group). First line chemotherapy was given for germ cell tumor in 159 patients (49.7{\%}), chemotherapy for teratoma with malignant transformation was performed in 14 (4.4{\%}) and only surgery was done in 147 (45.9{\%}). Median followup was 25.1 months (IQR 5.4-63.8). Five-year overall survival was 83.4{\%} (95{\%} CI 61.3 to 93.5) in patients with clinical stage I and it was also worse than expected in those with metastasis. On multivariable analyses nonprimitive neuroectodermal tumor histology (overall p = 0.004), gonadal primary tumor (p = 0.005) and fewer prior chemotherapy regimens (p",
keywords = "Cell transformation, neoplastic, Drug therapy, Neoplasms, germ cell and embryonal, Teratoma, Testicular neoplasms",
author = "Patrizia Giannatempo and Pond, {Gregory R.} and Guru Sonpavde and Costantine Albany and Yohann Loriot and Sweeney, {Christopher J.} and Roberto Salvioni and Maurizio Colecchia and Nicola Nicolai and Daniele Raggi and Rice, {Kevin R.} and Flack, {Chandra K.} and {El Mouallem}, {Nemer R.} and Hope Feldman and Karim Fizazi and Lawrence Einhorn and Richard Foster and Andrea Necchi and Cary, {K. Clinton}",
year = "2016",
doi = "10.1016/j.juro.2015.12.082",
language = "English (US)",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation

T2 - An International Collaboration

AU - Giannatempo, Patrizia

AU - Pond, Gregory R.

AU - Sonpavde, Guru

AU - Albany, Costantine

AU - Loriot, Yohann

AU - Sweeney, Christopher J.

AU - Salvioni, Roberto

AU - Colecchia, Maurizio

AU - Nicolai, Nicola

AU - Raggi, Daniele

AU - Rice, Kevin R.

AU - Flack, Chandra K.

AU - El Mouallem, Nemer R.

AU - Feldman, Hope

AU - Fizazi, Karim

AU - Einhorn, Lawrence

AU - Foster, Richard

AU - Necchi, Andrea

AU - Cary, K. Clinton

PY - 2016

Y1 - 2016

N2 - Purpose: We assessed prognostic factors, treatments and outcomes in patients with teratoma with malignant transformation, a rare occurrence among germ cell tumors. Materials and Methods: Data on patients diagnosed with teratoma with malignant transformation between June 1981 and August 2014 were collected across 5 referral centers. Chemotherapy was dichotomized as based on germ cell tumor or teratoma with malignant transformation. Cox analyses were done to evaluate prognostic factors of overall survival, the primary end point. Each factor was evaluated in a univariable model. Forward stepwise selection was used to construct an optimal model. Results: Among 320 patients the tumor primary site was gonadal in 287 (89.7%), retroperitoneal in 17 (5.3%) and mediastinal in 16 (5%). Teratoma with malignant transformation and germ cell tumor were diagnosed concurrently in 130 patients (40.6%). A total of 49 patients (16.8%) initially presented with clinical stage I. The remaining patients were at good (123 or 42.3%), intermediate (42 or 14.4%) and poor (77 or 26.5%) risk for metastasis according to IGCCCG (International Germ Cell Cancer Collaborative Group). First line chemotherapy was given for germ cell tumor in 159 patients (49.7%), chemotherapy for teratoma with malignant transformation was performed in 14 (4.4%) and only surgery was done in 147 (45.9%). Median followup was 25.1 months (IQR 5.4-63.8). Five-year overall survival was 83.4% (95% CI 61.3 to 93.5) in patients with clinical stage I and it was also worse than expected in those with metastasis. On multivariable analyses nonprimitive neuroectodermal tumor histology (overall p = 0.004), gonadal primary tumor (p = 0.005) and fewer prior chemotherapy regimens (p

AB - Purpose: We assessed prognostic factors, treatments and outcomes in patients with teratoma with malignant transformation, a rare occurrence among germ cell tumors. Materials and Methods: Data on patients diagnosed with teratoma with malignant transformation between June 1981 and August 2014 were collected across 5 referral centers. Chemotherapy was dichotomized as based on germ cell tumor or teratoma with malignant transformation. Cox analyses were done to evaluate prognostic factors of overall survival, the primary end point. Each factor was evaluated in a univariable model. Forward stepwise selection was used to construct an optimal model. Results: Among 320 patients the tumor primary site was gonadal in 287 (89.7%), retroperitoneal in 17 (5.3%) and mediastinal in 16 (5%). Teratoma with malignant transformation and germ cell tumor were diagnosed concurrently in 130 patients (40.6%). A total of 49 patients (16.8%) initially presented with clinical stage I. The remaining patients were at good (123 or 42.3%), intermediate (42 or 14.4%) and poor (77 or 26.5%) risk for metastasis according to IGCCCG (International Germ Cell Cancer Collaborative Group). First line chemotherapy was given for germ cell tumor in 159 patients (49.7%), chemotherapy for teratoma with malignant transformation was performed in 14 (4.4%) and only surgery was done in 147 (45.9%). Median followup was 25.1 months (IQR 5.4-63.8). Five-year overall survival was 83.4% (95% CI 61.3 to 93.5) in patients with clinical stage I and it was also worse than expected in those with metastasis. On multivariable analyses nonprimitive neuroectodermal tumor histology (overall p = 0.004), gonadal primary tumor (p = 0.005) and fewer prior chemotherapy regimens (p

KW - Cell transformation, neoplastic

KW - Drug therapy

KW - Neoplasms, germ cell and embryonal

KW - Teratoma

KW - Testicular neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84969534998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969534998&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2015.12.082

DO - 10.1016/j.juro.2015.12.082

M3 - Article

C2 - 26748165

AN - SCOPUS:84969534998

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

ER -